Vaccination cuts shingles incidence in HSC transplant patientsOctober 8, 2019
Bastidas et al found the herpes zoster vaccine (Shingrix) to be effective in patients who underwent autologous hematopoietic stem cell transplantation (HSCT). The phase III zoster efficacy trial tested a 2-dose course of the recombinant zoster vaccine in the HSC recipients. The study showed that during a median 21 months of follow-up, there was at least one herpes zoster case confirmed in 49 patients who received the vaccine and in 135 patients who received placebo (incidence rate ratio 0.32, 95% CI 0.22-0.44, P<0.001). Researchers conducted the study in 1846 patients undergoing HSCT (ZOE-HSCT) in 167 centres in 28 countries from July 2012 to February 2017. Those who had underwent HSCT in the past 50-70 days were involved in the study. Participants were randomized 1:1 to receive either the recombinant zoster vaccine or placebo in two 0.5 ml doses. The first dose was given 50-70 days following HSCT procedure and the second 1 to 2 months later. The findings showed that a 2-dose course of Shingrix could significantly reduce the incidence of herpes zoster over a median follow-up of 21 months.
Source: JAMA 9 July 2019;322(2):123-133. doi:10.1001/jama.2019.9053 https://jamanetwork.com/journals/jama/article-abstract/2737683